10-Q: Kiromic Biopharma Reports Q3 2024 Results Amidst Going Concern Uncertainty

Kiromic Biopharma's Q3 2024 report reveals ongoing losses and a going concern warning, despite clinical trial progress with Deltacel.

Summary

• Kiromic Biopharma reported a net loss of $7.4 million for the third quarter of 2024, and a net loss of $20.4 million for the nine months ended September 30, 2024.
• The company's research and development expenses increased to $4.2 million for the quarter and $11.4 million for the nine months, driven by the Deltacel program.
• General and administrative expenses were $2.4 million for the quarter and $6.7 million for the nine months.
• The company has a going concern warning due to insufficient cash to meet obligations for the next 12 months.
• Kiromic is exploring financing options, including equity or debt offerings, but there is no guarantee of success.
• The company's Deltacel-01 clinical trial has entered the dose-expansion phase with promising early results, including a 6-month median Progression Free Survival (PFS).
• Kiromic has issued $17.2 million in senior secured convertible promissory notes during the nine months ended September 30, 2024.
• The company has reclassified $19.8 million of convertible promissory notes and accrued interest into preferred shares during the nine months ended September 30, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is positive clinical trial progress and a Fast-Track Designation, the going concern warning and financial instability significantly dampen the overall sentiment. The company's reliance on debt financing and the high cash burn rate are also concerning.

Positives

• The Deltacel-01 clinical trial has shown promising early results with a 6-month median Progression Free Survival (PFS).
• The FDA granted Fast-Track Designation for Deltacel, which could expedite the approval process.
• The company has expanded its clinical trial sites to include Virginia Oncology Associates, Texas Oncology, UPMC Hillman Cancer Center, and the University of Arizona Cancer Center.
• Kiromic is actively developing Isocel and Procel product candidates, which are in the preclinical development stage.

Negatives

• The company has a going concern warning due to insufficient cash to meet obligations for the next 12 months.
• Kiromic has incurred significant losses and negative cash flows from operations since inception.
• The company's net loss for the quarter was $7.4 million, and $20.4 million for the nine months ended September 30, 2024.
• The company is reliant on additional financing to continue operations and fund research and development.
• There is no guarantee that the company will be able to secure additional financing on favorable terms.

Risks

• The company's ability to continue as a going concern is uncertain due to insufficient cash reserves.
• There is a risk that the company may need to file for bankruptcy if it cannot secure additional financing.
• The company's product candidates are still in early stages of clinical trials and development, and there is no guarantee of success.
• The company is subject to risks related to regulatory approvals, market acceptance, and competition.
• The company is dependent on contract research organizations and manufacturers.
• The company is subject to the risk of litigation and intellectual property infringement.

Future Outlook

The company plans to continue the development of Isocel and Procel, with IND submissions expected in the second half of 2025 and the second quarter of 2026, respectively, subject to sufficient financing. The company may initiate a registrational Phase 2 trial for Deltacel in the second half of 2025, depending on the response rates in the current Phase 1 trial.

Management Comments

• Management is evaluating different strategies to obtain the required funding for future operations.
• Management anticipates that existing cash resources will not be sufficient to meet operating and liquidity needs beyond December 2024.
• Management may further evaluate additional cost reduction actions, including additional reductions in our workforce and delay of research and development expenditures on one or more product candidates, in order to reduce our current expenditures and preserve cash.

Industry Context

The company is operating in the competitive field of cell therapy, specifically targeting solid tumors. The company's focus on allogeneic Gamma Delta T-cell therapy and its proprietary AI targeting and manufacturing technologies are aimed at differentiating it from competitors. The Fast-Track Designation for Deltacel is a positive development in the context of the industry's focus on expedited drug development.

Comparison to Industry Standards

• Kiromic's cash burn rate is high compared to other biotech companies at a similar stage of development, raising concerns about its financial sustainability.
• The company's reliance on convertible promissory notes for financing is not uncommon for early-stage biotech companies, but the high interest rates (25%) are a significant burden.
• The 6-month median PFS in the Deltacel-01 trial is a positive signal, but it is still early data and needs to be confirmed in larger trials.
• The company's focus on engineered GDT cells (Isocel and Procel) is aligned with the industry's trend towards more targeted and effective cell therapies.
• The company's going concern warning is a significant concern and is not typical for companies with promising clinical trial results.

Legal Proceedings

• The company is involved in ongoing litigation related to the Jason Terrel claim, which is currently under appeal in the Delaware Supreme Court.
• The company has settled the Karp and Podmore class action lawsuits for $2.3 million, with $1.73 million paid by the company.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern warning and potential need for bankruptcy.
• Employees may be impacted by potential workforce reductions and delays in research and development.
• Customers (potential patients) may be impacted by delays in the development and approval of the company's product candidates.
• Creditors face the risk of non-payment if the company is unable to secure additional financing.

Next Steps

• The company plans to continue the Deltacel-01 clinical trial, including the dose-expansion phase.
• The company plans to continue the development of Isocel and Procel, with IND submissions expected in the second half of 2025 and the second quarter of 2026, respectively.
• The company will seek additional financing to fund its operations and research and development activities.
• The company may initiate a registrational Phase 2 trial for Deltacel in the second half of 2025, depending on the response rates in the current Phase 1 trial.

Key Dates

Keywords

Kiromic Biopharma, Deltacel, Isocel, Procel, Gamma Delta T-cell therapy, clinical trials, biotherapeutics, oncology, FDA Fast-Track Designation, going concern, convertible promissory notes, preferred stock